Switch to:
Also traded in: France, Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.16
PM's Cash-to-Debt is ranked lower than
76% of the 42 Companies
in the Global Tobacco industry.

( Industry Median: 0.67 vs. PM: 0.16 )
Ranked among companies with meaningful Cash-to-Debt only.
PM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.13 Max: No Debt
Current: 0.16
Equity-to-Asset -0.34
PM's Equity-to-Asset is ranked lower than
93% of the 41 Companies
in the Global Tobacco industry.

( Industry Median: 0.45 vs. PM: -0.34 )
Ranked among companies with meaningful Equity-to-Asset only.
PM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.39  Med: 0.1 Max: 0.6
Current: -0.34
-0.39
0.6
Interest Coverage 12.05
PM's Interest Coverage is ranked lower than
64% of the 33 Companies
in the Global Tobacco industry.

( Industry Median: 28.23 vs. PM: 12.05 )
Ranked among companies with meaningful Interest Coverage only.
PM' s Interest Coverage Range Over the Past 10 Years
Min: 9.38  Med: 11.87 Max: 889.4
Current: 12.05
9.38
889.4
Piotroski F-Score: 7
Altman Z-Score: 5.01
Beneish M-Score: -2.36
WACC vs ROIC
6.45%
51.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 40.27
PM's Operating Margin % is ranked higher than
85% of the 41 Companies
in the Global Tobacco industry.

( Industry Median: 13.78 vs. PM: 40.27 )
Ranked among companies with meaningful Operating Margin % only.
PM' s Operating Margin % Range Over the Past 10 Years
Min: 38.99  Med: 40.32 Max: 44.18
Current: 40.27
38.99
44.18
Net Margin % 26.35
PM's Net Margin % is ranked higher than
79% of the 42 Companies
in the Global Tobacco industry.

( Industry Median: 8.81 vs. PM: 26.35 )
Ranked among companies with meaningful Net Margin % only.
PM' s Net Margin % Range Over the Past 10 Years
Min: 25.17  Med: 26.58 Max: 28.05
Current: 26.35
25.17
28.05
ROA % 19.69
PM's ROA % is ranked higher than
71% of the 42 Companies
in the Global Tobacco industry.

( Industry Median: 7.96 vs. PM: 19.69 )
Ranked among companies with meaningful ROA % only.
PM' s ROA % Range Over the Past 10 Years
Min: 18.78  Med: 20.86 Max: 24.36
Current: 19.69
18.78
24.36
ROC (Joel Greenblatt) % 153.41
PM's ROC (Joel Greenblatt) % is ranked higher than
79% of the 42 Companies
in the Global Tobacco industry.

( Industry Median: 35.14 vs. PM: 153.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 83.98  Med: 158.29 Max: 181.19
Current: 153.41
83.98
181.19
3-Year Revenue Growth Rate -3.70
PM's 3-Year Revenue Growth Rate is ranked lower than
79% of the 34 Companies
in the Global Tobacco industry.

( Industry Median: 4.10 vs. PM: -3.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -12.9  Med: 9.05 Max: 13
Current: -3.7
-12.9
13
3-Year EBITDA Growth Rate -5.50
PM's 3-Year EBITDA Growth Rate is ranked lower than
76% of the 33 Companies
in the Global Tobacco industry.

( Industry Median: 8.20 vs. PM: -5.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -5.5  Med: 10.55 Max: 16
Current: -5.5
-5.5
16
3-Year EPS without NRI Growth Rate -5.20
PM's 3-Year EPS without NRI Growth Rate is ranked lower than
75% of the 32 Companies
in the Global Tobacco industry.

( Industry Median: 4.10 vs. PM: -5.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -5.2  Med: 8.75 Max: 16.9
Current: -5.2
-5.2
16.9
» PM's 10-Y Financials

Financials (Next Earnings Date: 2017-05-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

PM Guru Trades in Q2 2016

Caxton Associates 55,000 sh (New)
Louis Moore Bacon 3,849 sh (New)
Lee Ainslie 5,851,537 sh (New)
Paul Tudor Jones 11,837 sh (New)
Pioneer Investments 3,771 sh (+9.94%)
MS Global Franchise Fund 213,089 sh (+8.53%)
John Rogers 348,783 sh (+3.55%)
Charles Brandes 4,776 sh (+0.32%)
First Eagle Investment 13,000 sh (unchged)
Tom Gayner 114,500 sh (unchged)
Jeff Auxier 187,494 sh (unchged)
Dodge & Cox 19,900 sh (unchged)
David Dreman 1,150 sh (unchged)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Stanley Druckenmiller Sold Out
T Rowe Price Equity Income Fund 497,100 sh (-0.12%)
Tom Russo 10,490,864 sh (-0.20%)
Murray Stahl 31,308 sh (-0.88%)
Donald Yacktman 28,501 sh (-0.98%)
Mairs and Power 7,998 sh (-1.23%)
Diamond Hill Capital 1,148,255 sh (-2.91%)
Tweedy Browne Global Value 882,900 sh (-3.90%)
Ken Fisher 13,059 sh (-5.26%)
Barrow, Hanley, Mewhinney & Strauss 19,474,260 sh (-6.88%)
Tweedy Browne 1,471,747 sh (-18.14%)
NWQ Managers 316,994 sh (-18.29%)
Jeremy Grantham 6,183,936 sh (-24.52%)
Manning & Napier Advisors, Inc 10,710 sh (-71.09%)
Ruane Cunniff 6,385 sh (-92.90%)
» More
Q3 2016

PM Guru Trades in Q3 2016

Jim Simons 12,000 sh (New)
George Soros 11,305 sh (New)
Louis Moore Bacon 28,642 sh (+644.14%)
John Rogers 453,174 sh (+29.93%)
Lee Ainslie 7,226,591 sh (+23.50%)
NWQ Managers 342,700 sh (+8.11%)
MS Global Franchise Fund 220,831 sh (+3.63%)
Tweedy Browne Global Value 882,900 sh (unchged)
T Rowe Price Equity Income Fund 497,100 sh (unchged)
Donald Yacktman 28,501 sh (unchged)
Tom Gayner 114,500 sh (unchged)
First Eagle Investment 13,000 sh (unchged)
David Dreman 1,150 sh (unchged)
Dodge & Cox 19,900 sh (unchged)
Murray Stahl 31,308 sh (unchged)
Caxton Associates 55,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Ruane Cunniff Sold Out
Ken Fisher 13,043 sh (-0.12%)
Jeff Auxier 185,494 sh (-1.07%)
Tom Russo 10,314,013 sh (-1.69%)
Barrow, Hanley, Mewhinney & Strauss 18,830,903 sh (-3.30%)
Diamond Hill Capital 1,100,677 sh (-4.14%)
Charles Brandes 4,508 sh (-5.61%)
Tweedy Browne 1,386,581 sh (-5.79%)
Mairs and Power 7,285 sh (-8.91%)
Jeremy Grantham 5,263,093 sh (-14.89%)
Pioneer Investments 2,538 sh (-32.70%)
Paul Tudor Jones 2,225 sh (-81.20%)
» More
Q4 2016

PM Guru Trades in Q4 2016

Joel Greenblatt 458,877 sh (New)
Jim Simons 725,600 sh (+5946.67%)
T Rowe Price Equity Income Fund 990,000 sh (+99.16%)
John Rogers 876,515 sh (+93.42%)
Paul Tudor Jones 3,023 sh (+35.87%)
MS Global Franchise Fund 299,480 sh (+35.62%)
Diamond Hill Capital 1,295,926 sh (+17.74%)
Pioneer Investments 2,851 sh (+12.33%)
Jeff Auxier 201,358 sh (+8.55%)
Ken Fisher 13,754 sh (+5.45%)
Charles Brandes 4,727 sh (+4.86%)
Tom Russo 10,363,811 sh (+0.48%)
Tweedy Browne Global Value 882,900 sh (unchged)
Donald Yacktman 28,501 sh (unchged)
First Eagle Investment 13,000 sh (unchged)
Tom Gayner 114,500 sh (unchged)
Mairs and Power 7,285 sh (unchged)
Dodge & Cox 19,900 sh (unchged)
David Dreman Sold Out
George Soros Sold Out
Caxton Associates Sold Out
Murray Stahl 31,106 sh (-0.65%)
Barrow, Hanley, Mewhinney & Strauss 18,491,673 sh (-1.80%)
NWQ Managers 329,207 sh (-3.94%)
Tweedy Browne 1,273,219 sh (-8.18%)
Jeremy Grantham 3,703,201 sh (-29.64%)
Lee Ainslie 35,850 sh (-99.50%)
» More
Q1 2017

PM Guru Trades in Q1 2017

T Rowe Price Equity Income Fund 1,270,000 sh (+28.28%)
Tweedy Browne Global Value 882,900 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Tobacco Products » Tobacco    NAICS: 312230    SIC: 2111
Compare:NYSE:MO, OTCPK:BTAFF, NYSE:RAI, OTCPK:JAPAY, OTCPK:IMBBF, OTCPK:GGNPF, OTCPK:SWMAY, NYSE:VGR, NYSE:UVV, NYSE:TPB, NYSE:AOI, OTCPK:MCIG, OTCPK:BXNG, OTCPK:VPRB, OTCPK:GLLA, OTCPK:MFST, OTCPK:SRUP, OTCPK:NHLE, OTCPK:RCGR, OTCPK:VAPI » details
Traded in other countries:PM.France, 4I1.Germany, PMI.Switzerland, 0M8V.UK,
Headquarter Location:USA
Philip Morris International Inc is a holding company. The Company through its subsidiaries manufactures and sells cigarettes and other tobacco products in markets outside the United States of America.

Philip Morris International is the world's second- largest tobacco company, behind China National Tobacco, and holds 28% of the global market, excluding China and the US. The firm owns seven of the leading 15 international brands. Marlboro, the company's flagship brand, accounted for just over one third of total volume in 2015. Other key brands include L&M, Philip Morris, Bond Street, Chesterfield, Parliament, and Lark.

Top Ranked Articles about Philip Morris International Inc

Philip Morris Files Product Application With FDA Once granted it will have a positive impact on the company's revenue
Philip Morris International Inc. (NYSE:PM) filed a Premarket Tobacco Product Application for its electronically heated tobacco product (EHTP) with the Food and Drug Administration's (FDA) Center for Tobacco Products March 31, according to the Business Wire. Read more...
Philip Morris Downgraded by Bank of America Merrill Lynch Analysts expect a target price of $100
On Jan. 4, Bank of America Merrill Lynch downgraded Philip Morris International Inc. (NYSE:PM) from Buy to Neutral, and the average target price set by analysts is now $100.69. Read more...
EU Supports Joint Operation of Illicit Cigarette Tracking by Tobacco Companies, 3rd Parties The tobacco industry wants to run the anti-smuggling and counterfeiting system to prevent profit loss
According to the findings of research commissioned by the European Union that was publicized by health charity Ash (Action on Smoking and Health) through a Financial Times article, an extensive European system that tracks illicit cigarettes should be operated by tobacco manufacturers and independent third parties. Read more...
23 Questions With Mike Onghai 'There is a big difference between a favorite company and a good stock'
1. How and why did you get started investing? Read more...
Lee Ainslie’s Top 3 New Holdings Guru buys Philip Morris, Computer Sciences and Mylan
Lee Ainslie (Trades, Portfolio) of Maverick Capital Ltd. acquired 32 new holdings in the second quarter. Among them were Philip Morris International Inc. (NYSE:PM), Computer Sciences Corp. (CSC) and Mylan NV (NASDAQ:MYL). Read more...
Prism Medical Ltd. Agrees to Be Acquired by Handicare Group AB

Agreement Provides for All Cash Consideration of $12.50 Per Share

TORONTO, ONTARIO and KISTA, SWEDEN--(Marketwired - Jun 27, 2016) - Prism Medical Ltd. ("Prism Medical") (TSX VENTURE:PM) and Handicare Group AB ("Handicare") today announced that they have entered into an arrangement agreement (the "Arrangement Agreement") pursuant to which Handicare will acquire all of the outstanding common shares of Prism Medical (the "Prism Medical Shares"). Pursuant to the Arrangement Agreement, shareholders of Prism Medical will receive $12.50 in cash for each Prism Medical Share, which represents a 31.6% premium to the closing price of the Prism Medical Shares on the TSX Venture Exchange (the "TSXV") on June 27, 2016 of $9.50 and a premium of 34.2% to the 20-trading day volume weighted average trading price of the Prism Medical Shares on the TSXV. The total equity purchase price is approximately $62 million on a fully diluted basis. Handicare is a Sweden based company which supplies technical aids for the elderly and physically disabled. Its products include homecare products (such as stairlifts), patient handling and bathroom safety products, and personal transfer and automobile adaptation solutions. Handicare is owned by Nordic Capital Fund VII. "The knowledge of our employees applied with passion to solve the moving and handling problems of the mobility disadvantaged and their caregivers in all health environments, has made Prism Medical a leader in its field. Handicare has a similar values profile, has recognized what our team has accomplished, and should add value for all stakeholders as the two companies combine their market leading products and service capabilities," said Andrew McIntyre, Chairman of Prism Medical. "Through this acquisition Handicare will be able to access greater opportunities in the North American market. In addition, the combined product portfolio will be among the best in the industry and serve as a good platform for further growth," said Johan Ek, Chairman of Handicare. Transaction Details The transaction will be carried out by way of a court approved plan of arrangement under the Business Corporations Act (Ontario) (the "Arrangement") and will require the approval of, among others, (i) the holders of at least 66 2/3% of the Prism Medical Shares, and (ii) a majority of minority shareholders, present in person or represented by proxy at a special meeting of Prism Medical shareholders (the "Prism Medical Meeting") to be called to consider the Arrangement. The Prism Medical Meeting is expected to be held before the end of August, 2016 with completion of the transaction expected to follow shortly thereafter. In addition to shareholder and court approvals, the Arrangement is subject to other closing conditions customary in transactions of this nature. The Arrangement is not subject to a financing condition. Directors, senior executive officers and certain shareholders of Prism Medical, who together hold an aggregate of approximately 36% of the issued and outstanding Prism Medical Shares (calculated on a non-diluted basis), have entered into a voting agreement with Handicare and agreed to vote their Prism Medical Shares in favour of the Arrangement at the Prism Medical Meeting. Under the Arrangement, each holder of Prism Medical Shares will receive $12.50 in cash per Prism Medical Share and each outstanding stock option of Prism Medical will be cancelled at the effective time of the Arrangement in exchange for a cash payment equal to the amount by which the consideration per Prism Medical Share payable pursuant to the Arrangement exceeds the exercise price of such option. The Arrangement Agreement also includes a non-solicitation covenant on the part of Prism Medical, subject to customary "fiduciary out" provisions that entitle Prism Medical to consider and accept a superior proposal and a right in favour of Handicare to match any superior proposal. If the Arrangement Agreement is terminated in certain circumstances, including if Prism Medical enters into an agreement with respect to a superior proposal or if the Board of Directors of Prism Medical (the "Board") withdraws or modifies its recommendation with respect to the Arrangement, Handicare will be entitled to a termination fee of $2,250,000. Full details of the Arrangement will be included in an information circular to be mailed to Prism Medical shareholders in accordance with applicable securities laws. The Board, after consultation with its financial and legal advisors, unanimously recommends that Prism Medical shareholders vote in favour of the Arrangement. The Board has also received a fairness opinion from Canaccord Genuity Corp. in connection with the Arrangement to the effect that, as of the date of such opinion, and subject to the assumptions, limitations and qualifications set forth therein, the consideration to be received by Prism Medical's shareholders pursuant to the Arrangement is fair from a financial point of view. Complete details of the Arrangement are set out in the Arrangement Agreement, which will be filed by Prism Medical with Canadian securities regulators and will be available for viewing under Prism Medical's profile at www.sedar.com. Canaccord Genuity Corp. is acting as financial advisor to Prism Medical. Torys LLP is acting as legal counsel to Prism Medical. Fasken Martineau DuMoulin LLP is acting as legal counsel to Handicare. Unless otherwise stated, all amounts in this news release are expressed in Canadian dollars. ABOUT PRISM MEDICAL Prism Medical is a vertically integrated manufacturer and leading provider of equipment and services used to move and handle mobility challenged individuals in a safe and dignified manner. Prism Medical's products are marketed under the brand names of Prism Medical, ErgoSafe, Waverley Glen and Nightingale in the homecare, acute care and long-term care markets throughout North America. Prism Medical offers solutions that encourage improved care, quality of life and mobility, while seeking to lower the overall cost of the caregiving function in a number of ways, including reducing the incidence of handling-related injuries among caregivers. Through its network of dealers, Prism Medical provides an integrated suite of products and services that make homecare a viable option for many people. For further information visit Prism Medical's website at www.prismmedicalltd.com or www.sedar.com. ABOUT HANDICARE GROUP AB Handicare was founded in 1986 and supplies technical aids for the elderly and physically disabled. Its products include stairlifts, transfer and lifting products, automobile adaptation solutions and homecare products. Handicare's brand products are distributed through a comprehensive network of professional dealers and distributors in 30 countries around the world. Through its subsidiary Puls, the group is also a market leader in the sale of capital goods and consumables to hospitals and institutions in Norway. Handicare has 950 employees and its headquarters in Kista, Sweden, and has subsidiaries in Norway, Denmark, Germany, the Netherlands, England, Belgium, France, and the US. For more information, please see www.handicare.com. FORWARD-LOOKING STATEMENTS This press release contains forward-looking information within the meaning of applicable securities laws that reflects the current expectations of management of Prism Medical regarding the Arrangement and its consummation, including whether conditions to the consummation of the Arrangement will be satisfied, and the timing for completing the Arrangement. The words "may", "would", "could", "should", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "aim", "endeavour", "project", "continue", "predict", "potential", or the negative of these terms or other similar expressions have been used to identify these forward-looking statements. Forward-looking statements are based upon a number of assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond management's control, and that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking statements. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those expected or estimated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The following factors could cause actual results to differ materially from those discussed in the forward-looking information: failure to satisfy the conditions to completion of the Arrangement, including approval by Prism Medical's shareholders and court approval and the occurrence of any event, change or other circumstance that could give rise to the termination of the Arrangement Agreement. Additional risks and uncertainties regarding Prism Medical are described in its most recent financial statements and MD&A which are available on SEDAR at www.sedar.com. This forward-looking information represents management's views as of the date of this press release. While subsequent events and developments may cause such views to change, Prism Medical does not intend to update this forward-looking information, except as required by applicable securities laws.





Prism Medical Ltd.
Ross Scavuzzo
Chief Executive Officer
416-260-2145
[email protected]




Read more...
Prism Medical Announces Appointment of New Chief Financial Officer

TORONTO, ONTARIO--(Marketwired - Jun 10, 2016) - Prism Medical Ltd. ("Prism Medical" or the "Company") (TSX VENTURE:PM) is pleased to announce that Bill Edwards has been appointed as the Company's new Chief Financial Officer effective immediately, following the previously announced departure of Rose Papastamos. Mr. Edwards, CPA, CA has worked for Prism since May of 2009 and held a variety of senior positions in both finance and operations. Mr. Edwards has over 30 years of financial management experience and previously held senior financial positions with private and public companies involved in construction material manufacturing, distribution and mechanical contracting. "We are very pleased to have Bill Edwards join us. Bill brings valuable experience in operations as well as finance, which will be essential as we develop our service operations," said Ross Scavuzzo, President and Chief Executive Officer of the Company. About Prism Medical Ltd. Prism Medical is a vertically integrated manufacturer and leading provider of equipment and services used to move and handle mobility challenged individuals in a safe and dignified manner. Prism Medical's products are marketed under the brand names of Prism Medical, ErgoSafe, Waverly Glen and Nightingale in the homecare, acute care and long-term care markets throughout North America. The Company offers solutions that encourage improved care, quality of life and mobility, while seeking to lower the overall cost of the caregiving function in a number of ways, including reducing the incidence of handling-related injuries among caregivers. In addition, the Company through its network of Nightingale dealers provides an integrated suite of products and services that make home care a viable option for many people. For further information visit Prism Medical's website at www.prismmedicalltd.com or www.sedar.com.





Ross Scavuzzo
Chief Executive Officer
[email protected]
416-260-2145




Read more...
Prism Medical Announces Departure of Chief Financial Officer

TORONTO, ONTARIO--(Marketwired - Jun 9, 2016) - Prism Medical Ltd. ("Prism Medical" or the "Company") (TSX VENTURE:PM) today announced the departure, effective June 8, 2016, of the Company's Chief Financial Officer, Rose Papastamos. "On behalf of the Company and our Board of Directors, we thank Rose for her service to the Company and wish her well in her future endeavours," said Ross Scavuzzo, President and Chief Executive Officer of the Company. The Company is currently in advanced negotiations with a qualified candidate for the Chief Financial Officer position and anticipates finalizing an agreement this month. About Prism Medical Ltd. Prism Medical is a vertically integrated manufacturer and leading provider of equipment and services used to move and handle mobility challenged individuals in a safe and dignified manner. Prism Medical's products are marketed under the brand names of Prism Medical, ErgoSafe, Waverly Glen and Nightingale in the homecare, acute care and long-term care markets throughout North America. The Company offers solutions that encourage improved care, quality of life and mobility, while seeking to lower the overall cost of the caregiving function in a number of ways, including reducing the incidence of handling-related injuries among caregivers. In addition, the Company through its network of Nightingale dealers provides an integrated suite of products and services that make home care a viable option for many people. For further information visit Prism Medical's website at www.prismmedicalltd.com or www.sedar.com. Forward-looking statements This announcement may contain "forward-looking statements" within the meaning of applicable securities laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Prism to be materially different from those expressed or implied by such forward-looking statements. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements, except in accordance with applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.





Prism Medical Ltd.
Ross Scavuzzo
Chief Executive Officer
416-260-2145
[email protected]
www.prismmedicalltd.com




Read more...
Prism Medical Ltd. Announces the Completion of the Acquisition of the Lifts and Elevating Business from Shoppers Home Health Care

TORONTO, ONTARIO--(Marketwired - Jun 1, 2016) - Prism Medical Ltd. ("Prism" or the "Company"), (TSX VENTURE:PM), a leading provider of durable medical equipment and related services to the mobility challenged, today announced that it has completed the previously announced acquisition by the Company of certain assets of the institutional and residential moving, handling and accessibility businesses of Shoppers Home Health Care in the provinces of Ontario, Saskatchewan and Alberta. The purchased assets consist of agreed inventory, equipment, customer contracts and goodwill of the acquired businesses. In addition, Prism agreed to hire certain employees, lease vehicles required by such employees and assume and perform certain contracts including customer contracts and a lease of premises located in Regina, Saskatchewan. "This transaction will allow us to focus Prism's core business activities and will further Prism's position as the leading Canadian manufacturer and distributer of moving and handling devices," said Ross Scavuzzo, CEO of Prism. "We look forward to continuing to deliver the outstanding level of customer services Shoppers Home Health Care has provided to a broad base of acute care and long term care facilities." About Prism Medical Ltd. Prism is a vertically integrated manufacturer and leading provider of equipment and services used to move and handle mobility challenged individuals in a safe and dignified manner. Prism's products are marketed under the brand names of Prism Medical, ErgoSafe, Waverly Glen and Nightingale in the homecare, acute care and long-term care markets throughout North America. The Company offers solutions that encourage improved care, quality of life and mobility, while seeking to lower the overall cost of the care giving function in a number of ways, including reducing the incidence of handling-related injuries among caregivers. In addition, the Company through its network of Nightingale dealers provides an integrated suite of products and services that make home care a viable option for many people. For further information visit Prism's website at www.prismmedicalltd.com or www.sedar.com. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. Source: Prism Medical Ltd. Forward looking statements This announcement may contain "forward-looking statements" within the meaning of applicable securities laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Prism to be materially different from those expressed or implied by such forward-looking statements. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.





Ross Scavuzzo
Prism Medical Ltd.
[email protected]
416-260-2145 ext. 235
Lana Gogas
Shoppers Drug Mart
416.493.1220, ext. 5141
[email protected]




Read more...
Prism Medical Reports Results for the First Quarter Ended February 29, 2016

TORONTO, ONTARIO--(Marketwired - Apr 28, 2016) - Prism Medical Ltd., ("Prism Medical" or "the Company") (TSX VENTURE:PM), a leading provider of durable medical equipment and related services to the mobility challenged, today reported financial results for the first quarter (Q1) ended February 29, 2016. Highlights for the three months ending February 29, 2016 compared to three months ended February 28, 2015:

Revenues of $14.7 Million, up $2.5 Million or 20%
Gross Margin of $6.0 Million, up $1.35 Million or 29%
Adjusted EBITDA1 of $1.5 Million, up $0.25 Million or 20%

Chief Executive's message: Ross Scavuzzo, Chief Executive Officer stated "We are pleased with the sales growth in all facets of our Canadian operations. Further positive results should result from the previously announced acquisition of our distributors business in Ontario, Saskatchewan and Alberta which is expected to close May 31, 2016. Our USA Homecare and company owned dealer segments achieved above average sales growth. The Company intends to grow sales and profitability and provide a reasonable return on shareholders' equity with a focus on the North American market. The Company believes that performance will be positively affected by a continued North American institutional and homecare demand for our products, improved manufacturing efficiencies, greater geographic coverage, and revenues and profits from new product introductions. During the past year the Company's North American operations have materially improved, driven by the additions of quality people and new customers and products. Management believes that there are significant growth opportunities within the expanding North American health care industry both through organic growth and acquisitions that offer the potential to significantly increase shareholder value, while remaining consistent with Prism Medical's key growth strategies of vertical integration, product diversification and the application of relevant knowledge by its services oriented personnel. The 2015 focus on building a strong foundation for growth will continue in 2016 and be sustained by greater positive growth in profits. The demand for our core products and services, in management's estimation, continues to experience growth at different rates in the geographic markets in which we participate. Government funding for our products in Canada is a key driver of sales. Although government policies related to healthcare in the markets we operate continue to change, we believe that the long term trend for our product solutions will be favourable. Management believes that the US market holds the greatest long-term potential to provide above-average revenue growth both in the institutional and home care markets. Budget constraints and the cyclical nature of the institutional order causes variability in USA revenue pipeline, which mask our efforts to gain market share. While the Company has no formal policy on dividend payments and the Board of Directors determines the suitability of such payments on a quarterly basis, the Company views dividend payments as an important part of its investor strategy and expects to continue its historical pattern of four dividend payments per fiscal year. Financial Results for First Quarter (Q1) ended February 29, 2016:





Three months ended February 29/28



(Expressed in thousands of Canadian dollars except for earnings per share and where otherwise noted)
2016

$

2015

$



Revenues
14,678

12,181



Gross margin
6,023

4,677




(as % of revenues)
41.0
%
38.4
%









Net income (loss)
57

402




(as % of revenues)
0.4
%
3.3
%









Non-IFRS Adjusted EBITDA
1,515

1,262




(as % of revenues)
10.3
%
10.4
%









Basic earnings per share







From continuing operations
0.01

0.08



Diluted earnings per share







From continuing operations
0.01

0.08




























As at February 29, 2016

$
As at November 30, 2015

$


Total Assets
51,974
51,001


Total Liabilities
23,177
26,969







Cash and Cash Equivalents
941
600


Bank indebtedness
4,158
3,236







Long Term Debt
11,861
12,325


Shareholders' Equity
24,503
24,032


Common Shares (In thousands)
4,939
4,939



Dividend Declaration On April 27, 2016, the Board of Directors approved the payment of $0.125 per common share to shareholders of record on May 13, 2016 to be paid on June 3, 2016. This is an eligible dividend within the Income Tax Act. About Prism Medical Ltd. Prism Medical is a vertically integrated manufacturer and leading provider of equipment and services used to move and handle mobility challenged individuals in a safe and dignified manner. Prism Medical's products are marketed under the brand names of Prism Medical, ErgoSafe, Waverly Glen and Nightingale in the homecare, acute care and long-term care markets throughout North America. The Company offers solutions that encourage improved care, quality of life and mobility, while seeking to lower the overall cost of the caregiving function in a number of ways, including reducing the incidence of handling-related injuries among caregivers. In addition, the Company through its network of Nightingale dealers provides an integrated suite of products and services that make home care a viable option for many people. For further information visit Prism Medical's website at www.prismmedicalltd.com or www.sedar.com. Non-IFRS Financial Measures Management uses Non-IFRS measures described herein to assess operating performance, to provide more meaningful period-to-period comparisons of operating results and provide investors understanding of core business operations. We believe the non-IFRS measures presented herein are useful to investors as they enable investors to evaluate and compare our results by excluding specific items that we do not consider to reflective of our ongoing operating results largely from management's determination that the facts and circumstances surrounding the excluded charges or recoveries are not indicative of the ordinary course of the ongoing operations of our business. We believe investors use both IFRS and non-IFRS measures to assess operations and financial results. Starting in Q1 2016, management determined that the definition of Non-IFRS Adjusted EBITDA would be revised and Pro-forma Adjusted EBITDA would no longer be disclosed. The newly revised definition of Non-IFRS Adjusted EBITDA now excludes the following items from IFRS Net Income (loss), where applicable: Amortization and depreciation, interest expense, income tax expense (recovery), stock-based compensation expense, gains or losses from discontinued operations (including gains or losses on the sale of business), foreign exchange gains or losses, restructuring costs, qualifying strategic initiatives, and acquisition and integration costs. We believe these costs are not directly related to ongoing operating results and do not reflect expected future operating expenses after completion of these activities. Acquisition and integration costs may include the cost of legal, due diligence, external consultant and other costs relating to acquisitions and their integration into the Company within one year of the date of acquisition. Strategic initiatives may include various non-recurring activities of the company that contribute to long-term growth and profitability including valuations, system implementations, and market studies. Restructuring is a program planned and controlled by management that materially changes the scope of the business or the manner in which it is conducted. Restructuring costs include charges relating to workforce reductions, site consolidations and costs associated with exiting businesses. Restructuring costs include employee severance and benefit costs, gains, losses or impairments related to owned sites and equipment we no longer use and which are available for sale, impairment of related intangible assets, and costs related to leased sites and equipment we no longer use. Forward-Looking Information This document contains forward-looking statements relating to our operations and to the environment in which we operate and our strategy, action plans and investments, which may involve estimates, forecasts and projections. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and/or are beyond our control. A number of important factors could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. These factors include those set forth in this report and our other public filings. Consequently, readers should not place any undue reliance on such forward-looking statements. These forward-looking statements are made as of the date of this report. Prism Medical is under no obligation to update any forward-looking statements contained herein should material facts change due to new information, future events or other factors. All forward-looking statements attributable to Prism Medical are expressly qualified by these cautionary statements. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. Complete financial statements and management's discussion and analysis for 2015 will be available shortly at www.PrismMedicalLtd.com and Sedar web-site.


1
See Non-IFRS Financial Measures section









Prism Medical Ltd.
Ross Scavuzzo
Chief Executive Officer
416-260-2145 x.238
[email protected]
www.PrismMedicalLtd.com




Read more...

Ratios

vs
industry
vs
history
PE Ratio 24.87
PM's PE Ratio is ranked lower than
70% of the 30 Companies
in the Global Tobacco industry.

( Industry Median: 17.38 vs. PM: 24.87 )
Ranked among companies with meaningful PE Ratio only.
PM' s PE Ratio Range Over the Past 10 Years
Min: 10.11  Med: 16.8 Max: 25.36
Current: 24.87
10.11
25.36
Forward PE Ratio 22.57
PM's Forward PE Ratio is ranked lower than
87% of the 30 Companies
in the Global Tobacco industry.

( Industry Median: 17.79 vs. PM: 22.57 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 24.87
PM's PE Ratio without NRI is ranked lower than
70% of the 30 Companies
in the Global Tobacco industry.

( Industry Median: 17.02 vs. PM: 24.87 )
Ranked among companies with meaningful PE Ratio without NRI only.
PM' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.11  Med: 16.8 Max: 25.36
Current: 24.87
10.11
25.36
Price-to-Owner-Earnings 25.43
PM's Price-to-Owner-Earnings is ranked lower than
77% of the 22 Companies
in the Global Tobacco industry.

( Industry Median: 17.45 vs. PM: 25.43 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PM' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.3  Med: 18.66 Max: 26.37
Current: 25.43
10.3
26.37
PS Ratio 6.55
PM's PS Ratio is ranked lower than
73% of the 40 Companies
in the Global Tobacco industry.

( Industry Median: 3.02 vs. PM: 6.55 )
Ranked among companies with meaningful PS Ratio only.
PM' s PS Ratio Range Over the Past 10 Years
Min: 2.71  Med: 4.47 Max: 6.6
Current: 6.55
2.71
6.6
Price-to-Free-Cash-Flow 25.24
PM's Price-to-Free-Cash-Flow is ranked lower than
54% of the 24 Companies
in the Global Tobacco industry.

( Industry Median: 25.12 vs. PM: 25.24 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PM' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.1  Med: 17.42 Max: 25.52
Current: 25.24
10.1
25.52
Price-to-Operating-Cash-Flow 21.55
PM's Price-to-Operating-Cash-Flow is ranked lower than
65% of the 26 Companies
in the Global Tobacco industry.

( Industry Median: 17.92 vs. PM: 21.55 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PM' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.82  Med: 15.33 Max: 21.81
Current: 21.55
8.82
21.81
EV-to-EBIT 18.91
PM's EV-to-EBIT is ranked lower than
90% of the 52 Companies
in the Global Tobacco industry.

( Industry Median: 9.79 vs. PM: 18.91 )
Ranked among companies with meaningful EV-to-EBIT only.
PM' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 12.1 Max: 18.95
Current: 18.91
7.8
18.95
EV-to-EBITDA 17.94
PM's EV-to-EBITDA is ranked lower than
98% of the 49 Companies
in the Global Tobacco industry.

( Industry Median: 9.27 vs. PM: 17.94 )
Ranked among companies with meaningful EV-to-EBITDA only.
PM' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.2  Med: 11.3 Max: 17.98
Current: 17.94
7.2
17.98
Shiller PE Ratio 24.76
PM's Shiller PE Ratio is ranked lower than
54% of the 13 Companies
in the Global Tobacco industry.

( Industry Median: 23.07 vs. PM: 24.76 )
Ranked among companies with meaningful Shiller PE Ratio only.
PM' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.4  Med: 22.28 Max: 25.02
Current: 24.76
19.4
25.02
Current Ratio 1.07
PM's Current Ratio is ranked lower than
72% of the 39 Companies
in the Global Tobacco industry.

( Industry Median: 1.50 vs. PM: 1.07 )
Ranked among companies with meaningful Current Ratio only.
PM' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.07 Max: 1.83
Current: 1.07
0.97
1.83
Quick Ratio 0.52
PM's Quick Ratio is ranked lower than
77% of the 39 Companies
in the Global Tobacco industry.

( Industry Median: 0.88 vs. PM: 0.52 )
Ranked among companies with meaningful Quick Ratio only.
PM' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 0.49 Max: 0.73
Current: 0.52
0.41
0.73
Days Inventory 321.10
PM's Days Inventory is ranked lower than
90% of the 40 Companies
in the Global Tobacco industry.

( Industry Median: 123.38 vs. PM: 321.10 )
Ranked among companies with meaningful Days Inventory only.
PM' s Days Inventory Range Over the Past 10 Years
Min: 280.93  Med: 331.03 Max: 381.73
Current: 321.1
280.93
381.73
Days Sales Outstanding 47.89
PM's Days Sales Outstanding is ranked lower than
71% of the 35 Companies
in the Global Tobacco industry.

( Industry Median: 23.35 vs. PM: 47.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
PM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 37.57  Med: 43.4 Max: 53.7
Current: 47.89
37.57
53.7
Days Payable 64.20
PM's Days Payable is ranked higher than
68% of the 28 Companies
in the Global Tobacco industry.

( Industry Median: 51.99 vs. PM: 64.20 )
Ranked among companies with meaningful Days Payable only.
PM' s Days Payable Range Over the Past 10 Years
Min: 27.11  Med: 39.23 Max: 64.75
Current: 64.2
27.11
64.75

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.69
PM's Dividend Yield % is ranked lower than
73% of the 48 Companies
in the Global Tobacco industry.

( Industry Median: 4.02 vs. PM: 3.69 )
Ranked among companies with meaningful Dividend Yield % only.
PM' s Dividend Yield % Range Over the Past 10 Years
Min: 0.83  Med: 4.17 Max: 6.24
Current: 3.69
0.83
6.24
Dividend Payout Ratio 0.92
PM's Dividend Payout Ratio is ranked lower than
79% of the 33 Companies
in the Global Tobacco industry.

( Industry Median: 0.59 vs. PM: 0.92 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PM' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.47  Med: 0.68 Max: 0.92
Current: 0.92
0.47
0.92
3-Year Dividend Growth Rate 4.80
PM's 3-Year Dividend Growth Rate is ranked lower than
57% of the 21 Companies
in the Global Tobacco industry.

( Industry Median: 6.20 vs. PM: 4.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PM' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 6.2 Max: 22.3
Current: 4.8
0
22.3
Forward Dividend Yield % 3.79
PM's Forward Dividend Yield % is ranked lower than
67% of the 52 Companies
in the Global Tobacco industry.

( Industry Median: 3.98 vs. PM: 3.79 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.37
PM's 5-Year Yield-on-Cost % is ranked lower than
64% of the 53 Companies
in the Global Tobacco industry.

( Industry Median: 5.83 vs. PM: 5.37 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PM' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.21  Med: 6.07 Max: 9.08
Current: 5.37
1.21
9.08
3-Year Average Share Buyback Ratio 0.80
PM's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 17 Companies
in the Global Tobacco industry.

( Industry Median: 0.40 vs. PM: 0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.2  Med: 3.6 Max: 5.1
Current: 0.8
-1.2
5.1

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.94
PM's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
75% of the 16 Companies
in the Global Tobacco industry.

( Industry Median: 2.25 vs. PM: 2.94 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PM' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.3  Med: 1.84 Max: 2.95
Current: 2.94
1.3
2.95
Price-to-Median-PS-Value 1.46
PM's Price-to-Median-PS-Value is ranked lower than
74% of the 38 Companies
in the Global Tobacco industry.

( Industry Median: 1.17 vs. PM: 1.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.79  Med: 1 Max: 1.46
Current: 1.46
0.79
1.46
Earnings Yield (Greenblatt) % 5.29
PM's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 50 Companies
in the Global Tobacco industry.

( Industry Median: 10.21 vs. PM: 5.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5.28  Med: 8.3 Max: 12.8
Current: 5.29
5.28
12.8
Forward Rate of Return (Yacktman) % 0.35
PM's Forward Rate of Return (Yacktman) % is ranked lower than
94% of the 18 Companies
in the Global Tobacco industry.

( Industry Median: 12.52 vs. PM: 0.35 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PM' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.2  Med: 13.5 Max: 32.5
Current: 0.35
0.2
32.5

More Statistics

Revenue (TTM) (Mil) $26,666
EPS (TTM) $ 4.52
Beta0.81
Short Percentage of Float0.70%
52-Week Range $86.78 - 115.63
Shares Outstanding (Mil)1,553.14

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 28,410 30,911 33,097
EPS ($) 4.90 5.42 6.07
EPS without NRI ($) 4.90 5.42 6.07
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.00%
Dividends per Share ($) 4.32 4.50 4.74
» More Articles for PM

Headlines

Articles On GuruFocus.com
Philip Morris Files Product Application With FDA Apr 03 2017 
22 Questions With the Founder of Sure Dividend Mar 22 2017 
Joel Greenblatt Raises Holdings of CVS Health, Priceline, HP Mar 21 2017 
A Good Long Idea in the Past, Most Valuable in the Future Mar 02 2017 
Buffett Stocks in Focus: Mondelez International Mar 01 2017 
Philip Morris Beats Expectations Feb 03 2017 
A Popular High Dividend Stock for Retirement Portfolios Feb 03 2017 
Altria: The World’s Best Investment Jan 26 2017 
4 Reasons I Prefer Philip Morris Over Altria Jan 26 2017 
Philip Morris Downgraded by Bank of America Merrill Lynch Jan 07 2017 

More From Other Websites
Philip Morris International, Inc. – Value Analysis (NYSE:PM) : April 24, 2017 Apr 24 2017
Philip Morris Q1 Results Disappoint: ETFs in Focus Apr 24 2017
Earnings Season Scorecard & Today's Top Stock Research Reports Apr 24 2017
[$$] Against All Odds, the U.S. Tobacco Industry Is Rolling in Money Apr 23 2017
Should Investors Sell on Philip Morris’ Q1 Miss? Apr 21 2017
Stock Market News for April 21, 2017 Apr 21 2017
Philip Morris's Bad Quarter: Not So Bad After All? Apr 21 2017
Philip Morris International, Inc. breached its 50 day moving average in a Bearish Manner : PM-US :... Apr 21 2017
Plunging Cigarette Shipments Hurt Philip Morris International Apr 20 2017
Philip Morris (PM) Earnings, Sales Miss Estimates in Q1 Apr 20 2017
Philip Morris: Up in Smoke? Apr 20 2017
US STOCKS-Wall St opens higher as earnings season kicks into gear Apr 20 2017
Philip Morris (PM) Misses Q1 Earnings and Sales; Stock Down Apr 20 2017
Why Philip Morris Earnings Went Up in Smoke Apr 20 2017
Dow set to claw its way back from triple-digit loss as oil prices rebound Apr 20 2017
Philip Morris misses 1Q profit forecasts Apr 20 2017
Philip Morris shares slump after earnings miss Apr 20 2017
Philip Morris International Inc. (PMI) Reports 2017 First-Quarter Results; Increases, for Favorable... Apr 20 2017
Visa, Verizon, and claims — What you need to know in markets on Thursday Apr 19 2017
This Will Make or Break Philip Morris International Tomorrow Apr 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)